Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection

Katharine Orf¹, Srdan Rogosic¹, Daniel Dexter¹, Phil Ancliff¹, Saket Badle¹, Joe Brierley², Danny Cheng³, Caroline Dalton³, Garth Dixon⁴, Pascale Du Pré⁵, Louis Grandjean⁶,⁷, Sara Ghorashian¹, Prabal Mittal¹, David O’Connor¹,⁸, Vesna Pavasovic¹, Anupama Rao¹, Sujith Samarasinghe¹, Ajay Vora¹, Alasdair Bamford⁶,⁷, Jack Bartram¹,⁷

¹Department of Haematology, Great Ormond Street Hospital for Children NHS Trust, London, UK
²Paediatric Bioethics Centre, Great Ormond Street Hospital for Children NHS Trust, London
³Department of Pharmacy, Great Ormond Street Hospital for Children NHS Trust
⁴Department of Microbiology, Great Ormond Street Hospital for Children NHS Trust
⁵Department of Paediatric Intensive Care, Great Ormond Street Hospital for Children NHS Trust
⁶Department of Infectious Diseases, Great Ormond Street Hospital for Children NHS Trust, London, UK
⁷UCL Great Ormond Street Institute of Child Health
⁸UCL Cancer Institute, London, UK

*Corresponding author

The COVID-19 pandemic potentially makes treatment of acute leukaemia more difficult. Most induction chemotherapy regimens for acute leukaemia lead to extended periods of cytopaenia and immunosuppression rendering patients vulnerable to opportunistic infections. As with many aspects of SARS-CoV-2, there is no universally accepted way of treating patients who present with acute leukaemia and associated infection. The limited data available so far on the outcomes of patients with cancer presenting with COVID-19 suggest they have increased risk of complications and mortality (Moujaess, et al 2020). Paediatric patients exhibit milder symptoms of COVID-19 and a less severe disease course but there is little data available on paediatric haemato-oncology patients (Lu, et al 2020) (de Rojas, et al 2020) (Balduzzi, et al 2020) (Du, et al 2020). The optimal treatment of children with cancer and concurrent COVID-19 is unclear and requires case by case discussion with individualised management plans. Several different antiviral and immunomodulatory therapies have been trialled in patients presenting with COVID-19. Remdesivir has shown in vitro activity against SARS-CoV-2, the virus that causes COVID-19. The data available on use suggest clinical benefit, with recent guidelines recommending consideration of its use in severe infections (Grein, et al 2020) (Beigel, et al 2020) (Wang, et al 2020). There is limited evidence on safety in paediatric use of remdesivir. However, adult data are reassuring from a safety perspective, with major adverse events

We report the use of remdesivir in a previously well five-year old child diagnosed with precursor B-cell acute lymphoblastic leukaemia and concomitant SARS-CoV-2 infection. He was hospitalised with a short history of fever, petechiae and neck swelling. On initial assessment he was found to have large bilateral neck swelling with associated swollen lip and tongue. He had inspiratory stridor, oxygen saturations were normal. He was initially treated with nebulised adrenaline and a single dose of oral dexamethasone. A chest x-ray performed showed perihilar bronchial thickening with no other changes. Initial blood results showed anaemia with a haemoglobin 57 g/L, platelet count of 55 x 10^9/L and total white cell count 6.76 x 10^9/L. Circulating blasts were present on the peripheral blood film and flow cytometry on peripheral blood confirmed precursor B-cell ALL, NCI standard risk. He was transferred to the paediatric intensive care unit (PICU) due to concerns about need for airway support. Nasopharyngeal aspirate on admission to PICU was positive on SARS-CoV-2 RNA PCR performed on the QiAstat respiratory SARS-CoV-2 panel, an assay with 2-hour turnaround in our in house laboratory. Further history from the parents revealed they themselves had symptoms consistent with COVID-19 (high fevers, cough and anosmia) three weeks previously. Multidisciplinary team discussion between infectious diseases, haematology, pharmacy and PICU teams and an infectious diseases team from an external centre led to the decision to treat him with remdesivir for five days. Our trust had also set up a system in collaboration with the bioethics committee for expedited consideration and approval of unlicensed drugs in the context of the pandemic. The decision to treat was made because the patient was thought to be in the early stages of infection with SARS-CoV-2 and his need for urgent chemotherapy would lead to significant immunosuppression, due to high dose prolonged dexamethasone. There are no described significant predicted drug interaction between remdesivir and ALL induction chemotherapy (dexamethasone, vincristine and pegylated-asparaginase) as per https://www.covid19-druginteractions.org. His stridor settled without further intervention and he had a general anaesthetic for insertion of Portacath, bone marrow aspirate, diagnostic lumbar puncture and intrathecal methotrexate. Cytogenetics confirmed ETV6-RUNX1 rearrangement and cerebrospinal fluid was negative for leukaemic cells. Remdesivir was obtained on compassionate access programme from Gilead and started on day two of admission. Paediatric dosing for remdesivir is not yet established and current treatment protocols are based on dosing for Ebola. Our patient was treated initially with a loading dose of remdesivir at 5mg/kg intravenously, followed by 2.5mg/kg daily (Chiotos 2020). Chemotherapy as per UKALL 2019 interim guidelines three drug induction (regimen A therapy consisting of pegylated-asparaginase,
intrathecal methotrexate, vincristine and dexamethasone) was started the same day as remdesivir initiation.

He was monitored with daily blood tests including liver function testing during treatment. On day three his ALT began to increase from a normal level at diagnosis, reaching a peak of 408U/L (upper limit of normal 25 U/L) on day five. His ALP, albumin and bilirubin remained within normal limits. Although raised ALT is an expected finding during induction chemotherapy, remdesivir was discontinued as stipulated by the compassionate use guidelines; the patient had at this point completed four out of planned five days of treatment. Repeat SARS-CoV-2 testing by PCR on NPA at this point was negative, and he was found to have SARS-CoV-2 specific IgG antibodies in serum as tested by ELISA (EDI). Stool was test weekly in the first month and remained negative by PCR for SARS-CoV-2. Following cessation of remdesivir, ALT returned to normal limits within ten days. During his admission, he maintained normal saturations without requiring supplemental oxygen therapy. He had no further temperatures after starting remdesivir. He was discharged home on day 8 of induction and had no further unplanned admissions during induction. End of induction assessment showed his bone marrow in morphological remission with undetectable minimal residual disease. SARS-CoV-19 testing by PCR remains negative.

This is the first case described in the UK of treatment of a child with a new presentation of acute leukaemia and SARS-CoV-2 infection treated with antiviral therapy. He remained asymptomatic from SARS-CoV-2 and did not deteriorate with immunosuppressive chemotherapy. His initial low viral load, coupled with the timing of his parents’ symptoms of COVID-19 suggests that he had SARS-CoV-2 infection for some time prior to presentation with ALL. However, his risk of progression to severe infection was significant due to initiation of chemotherapy and high-dose steroids. Remdesivir therapy could be useful in similar high-risk periods or pre-emptively following exposure to SARS-CoV-2. In this case, remdesivir was well tolerated with no side effects except anticipated elevation in ALT which was more likely secondary to induction chemotherapy. It demonstrates the need for regular monitoring of liver function tests during therapy, as well as the difficulty of assessing safety profiles of medications when started in the acute phase of an illness when chemotherapy agents are started concurrently. On balance in this case remdesivir was discontinued as the child had clinically improved and SAR-CoV-2 PCR was negative. Further studies are needed to assess safety and efficacy of SARS-CoV-2 therapies in paediatric haematology patients with both symptomatic and asymptomatic infection.
Acknowledgments

We would like to thank the Infectious diseases team at St Marys Hospital, London for advising on the case (Dr Liz Whittaker, Dr Caroline Foster and Dr Hermione Lyall). We would like to thank the Children’s Acute Transport Service (CATS), staff of the Paediatric Intensive Care Unit and Haematology/Oncology Unit at Great Ormond Street Hospital. Thanks also to Gilead for access to remdesivir through a compassionate access scheme.

Author contributions

All authors provided clinical care for the patient and were involved in critically revising the manuscript. All authors have approved the final manuscript.

Conflicts of interest

AB has completed paid consultancy work for Gilead relating to the management of COVID-19 in children.

References


